Nuveen LLC Makes New $18.78 Million Investment in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Nuveen LLC acquired a new stake in Ultragenyx Pharmaceutical Inc., purchasing 518,543 shares valued at approximately $18.78 million.
• Ultragenyx reported a 13.2% increase in revenue year-over-year, totaling $166.50 million, and exceeded analysts' EPS estimates by $0.10.
• Institutional investors own 97.67% of Ultragenyx’s stock, indicating strong institutional support for the biopharmaceutical company.

Nuveen LLC acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 518,543 shares of the biopharmaceutical company's stock, valued at approximately $18,776,000. Nuveen LLC owned 0.55% of Ultragenyx Pharmaceutical as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Deep Track Capital LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $27,493,000. First Light Asset Management LLC increased its position in Ultragenyx Pharmaceutical by 1.1% in the 4th quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company's stock valued at $32,125,000 after acquiring an additional 8,505 shares during the period. Dark Forest Capital Management LP bought a new stake in Ultragenyx Pharmaceutical during the 4th quarter valued at $459,000. Stifel Financial Corp raised its stake in Ultragenyx Pharmaceutical by 13.5% during the 4th quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock valued at $1,001,000 after acquiring an additional 2,835 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in Ultragenyx Pharmaceutical by 23.1% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after acquiring an additional 269,733 shares during the period. 97.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RARE. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. Cantor Fitzgerald lowered their price objective on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Canaccord Genuity Group reduced their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th. Morgan Stanley decreased their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Finally, William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $81.50.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

RARE traded up $0.26 during mid-day trading on Friday, hitting $29.78. The stock had a trading volume of 1,267,904 shares, compared to its average volume of 1,721,914. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $60.37. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -5.39 and a beta of 0.25. The stock's fifty day simple moving average is $31.69 and its 200-day simple moving average is $35.79.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. During the same quarter in the previous year, the business posted ($1.52) EPS. The business's quarterly revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.